Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

治疗阿尔茨海默氏病有多少价值？ 对疾病改良疗法定价的成本效益阈值

卷 17, 期 9, 2020

页: [819 - 822] 页: 4

弟呕挨: 10.2174/1567205017666201203121907

价格: $65

摘要

背景：最近的试验表明，针对阿尔茨海默氏病的疾病改良疗法（DMT）可能很快就会面世。由于预期的高价和庞大的患者群体，预算影响将是巨大的。 目标：我们探讨了DMT具有成本效益的有效性和价格的组合。 方法：我们使用开源模型对付款人和社会观点，价格变动和治疗效果大小同时进行双向情景分析。该分析为美国65岁以上因阿尔茨海默氏病引起的轻度认知障碍的DMT有效性潜在范围内的成本效益阈值定价。 结果：在每个质量调整生命年的支付意愿门槛为150,000美元，并假设相对于护理标准降低了30％的风险，每位患者每年DMT的最高成本效益价格约为22,000美元，且从社会和付款人的角度来看分别为15,000美元。 结论：价格和治疗效果大小的共同变化可以帮助评估潜在的阿尔茨海默氏病治疗的成本效益。

关键词: 阿尔茨海默氏病，痴呆，轻度认知障碍，成本效益分析，定价，药物开发，疾病缓解疗法。

« Previous Next »
[1]
FDA Accepts . Biogen’s aducanumab biologics license application for Alzheimer’s disease with priority review Biogen Website 2020.https://investors.biogen.com/news-releases/news-release-details/fda-accepts-biogens-aducanumab-biologics-license-application
[2]
EISAI and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease At Alzheimer’s Association International Conference (AAIC) 2018.https://www.eisai.com/news/2018/news201866.html
[3]
Aisen PS. Continuing progress in Alzheimer’s disease trials: Cause for optimism. J Prev Alzheimers Dis 2017; 4(4): 211-2.
[http://dx.doi.org/10.14283/jpad.2017.34] [PMID: 29181483]
[4]
Sterner RM, Takahashi PY, Yu Ballard AC. Active vaccines for Alzheimer disease treatment. J Am Med Dir Assoc 2016; 17(9): 862.e11-5.
[http://dx.doi.org/10.1016/j.jamda.2016.06.009] [PMID: 27461865]
[5]
Goldman DP, Fillit H, Neumann P. Accelerating Alzheimer’s disease drug innovations from the research pipeline to patients. Alzheimers Dement 2018; 14(6): 833-6.
[http://dx.doi.org/10.1016/j.jalz.2018.02.007] [PMID: 29680407]
[6]
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019; 5: 272-93.
[http://dx.doi.org/10.1016/j.trci.2019.05.008] [PMID: 31334330]
[7]
Liu JL, Hlávka JP, Hillestad R, Mattke S. Assessing the preparedness of the US health care system infrastructure for an Alzheimer’s treatment St Monica, CA RAND Corp 2017.https://www.rand.org/pubs/research_reports/RR2272.html
[8]
Anderson R, Knapp M, Wittenberg R, Handels R, Schott JM. Economic modelling of disease-modifying therapies in Alzheimer’s disease Pers Soc Serv Res Unit, LSE Mar 2018.
[9]
Budd D, Burns LC, Guo Z, L’italien G, Lapuerta P. Impact of early intervention and disease modification in patients with predementia Alzheimer’s disease: A Markov model simulation. Clinicoecon Outcomes Res 2011; 3(1): 189-95.
[http://dx.doi.org/10.2147/CEOR.S22265] [PMID: 22046104]
[10]
Green C, Handels R, Gustavsson A, et al. Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework. Alzheimers Dement 2019; 15(10): 1309-21.
[http://dx.doi.org/10.1016/j.jalz.2019.05.004] [PMID: 31402324]
[11]
Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014; 371(9): 796-7.
[http://dx.doi.org/10.1056/NEJMp1405158] [PMID: 25162885]
[12]
Gustavsson A, Brinck P, Bergvall N, et al. Predictors of costs of care in Alzheimer’s disease: A multinational sample of 1222 patients. Alzheimers Dement 2011; 7(3): 318-27.
[http://dx.doi.org/10.1016/j.jalz.2010.09.001] [PMID: 21575872]
[13]
Marešová P, Dolejs J, Mohelska H, Bryan LK. Cost of treatment and care for people with Alzheimer’s disease: A meta- analysis. Curr Alzheimer Res 2019; 16(14): 1245-53.
[http://dx.doi.org/10.2174/1567205017666200102144640] [PMID: 31894748]
[14]
Wimo A, Jönsson L, Bond J, Prince M, Winblad B. Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013; 9(1): 1-11.e3.
[http://dx.doi.org/10.1016/j.jalz.2012.11.006] [PMID: 23305821]
[15]
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (EMERGE). Clinical Trials Website 2019.https://clinicaltrials.gov/ct2/show/NCT02484547
[16]
Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer’s disease: A cross-sectional study of patients and caregivers. Med Care 1999; 37(1): 27-32.
[http://dx.doi.org/10.1097/00005650-199901000-00005] [PMID: 10413389]
[17]
Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: A Review of measures for health services research in the United States. Health Serv Res 2018; 53(1): 175-96.
[http://dx.doi.org/10.1111/1475-6773.12612] [PMID: 27873305]
[18]
Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-Effectiveness in health and medicine. 2nd ed. New York, NY: Oxford University Press 2017.
[19]
Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer’s disease: A systematic review of cost-effectiveness analyses. Drugs 2012; 72(6): 789-802.
[http://dx.doi.org/10.2165/11631830-000000000-00000] [PMID: 22480339]
[20]
Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease--a simulation study. Curr Alzheimer Res 2013; 10(2): 207-16.
[http://dx.doi.org/10.2174/1567205011310020011] [PMID: 23036018]
[21]
Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019; 321(13): 1286-94.
[http://dx.doi.org/10.1001/jama.2019.2000] [PMID: 30938796]

Rights & Permissions Print Cite
Article Metrics
37
© 2024 Bentham Science Publishers | Privacy Policy